Research across Microsatellite-stable colorectal cancer
Related studies from across the Microsatellite-stable colorectal cancer family.
Phase I trial of regorafenib plus ipilimumab and nivolumab shows 27.6% response in MSS colorectal cancer
Who Really Responds to a Stubborn Colon Cancer Combo?
A phase I trial in 29 patients with microsatellite-stable metastatic colorectal cancer tested the combination of regorafenib, ipilimumab, an…
A three-drug combo helped some patients with stubborn colon cancer, and immune markers now predict who will benefit most.
Post hoc analysis links TMB ≥9 or BRAF-V600E to longer PFS with chemo-nivolumab in MSS/pMMR mCRC
Could two simple blood tests help predict which colon cancer patients benefit from immunotherapy?
A post hoc analysis of the METIMMOX RCT in patients with metastatic MSS/pMMR colorectal cancer found that in the experimental arm (alternati…
Two simple blood tests and tumor markers can predict which colon cancer patients live longer on immunotherapy combined with chemotherapy.